These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26121443)

  • 1. SERUM THYROTROPIN CONCENTRATIONS ARE NOT PREDICTIVE OF AGGRESSIVE BREAST CANCER BIOLOGY IN EUTHYROID INDIVIDUALS.
    Villa NM; Li N; Yeh MW; Hurvitz SA; Dawson NA; Leung AM
    Endocr Pract; 2015 Sep; 21(9):1040-5. PubMed ID: 26121443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
    Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
    Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
    Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
    J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.
    Shokouh TZ; Ezatollah A; Barand P
    Medicine (Baltimore); 2015 Aug; 94(32):e1359. PubMed ID: 26266392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women.
    Stark A; Kapke A; Schultz D; Brown R; Linden M; Raju U
    Breast Cancer Res Treat; 2008 Feb; 107(3):405-14. PubMed ID: 17431759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer.
    Shukla S; Singh BK; Pathania OP; Jain M
    Indian J Med Res; 2016 May; 143(Supplement):S52-S58. PubMed ID: 27748278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.
    Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Vergote I; Christiaens MR
    Ann Oncol; 2005 Nov; 16(11):1755-61. PubMed ID: 16085689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
    Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
    Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.
    Badowska-Kozakiewicz A; Sobol M; Patera J
    Adv Clin Exp Med; 2016; 25(4):741-50. PubMed ID: 27629849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
    Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of quantitative analysis to biologic profile evaluation in breast cancer.
    Querzoli P; Ferretti S; Albonico G; Magri E; Scapoli D; Indelli M; Nenci I
    Cancer; 1995 Dec; 76(12):2510-7. PubMed ID: 8625078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.
    Luyeye Mvila G; Batalansi D; Praet M; Marchal G; Laenen A; Christiaens MR; Brouckaert O; Ali-Risasi C; Neven P; Van Ongeval C
    Breast; 2015 Oct; 24(5):642-8. PubMed ID: 26279132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer.
    Albert JM; Gonzalez-Angulo AM; Guray M; Sahin A; Strom EA; Tereffe W; Woodward WA; Tucker SL; Hunt KK; Hortobagyi GN; Buchholz TA
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1296-302. PubMed ID: 20472353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
    Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
    Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.
    Ba JL; Liu CG; Jin F
    Asian Pac J Cancer Prev; 2014; 15(21):9233-9. PubMed ID: 25422206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.